Australia - englanti - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - tranexamic acid, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - intravenous administration,adults,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Yhdysvallat - englanti - NLM (National Library of Medicine)

acella pharmaceuticals - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 100 mg in 1 ml - tranexamic acid injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: - in patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity (see warnings). - in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection  in such patients. - in patients with active intravascular clotting. - in patients with hypersensitivity to tranexamic acid or any of the ingredients

Yhdysvallat - englanti - NLM (National Library of Medicine)

nexus pharmaceuticals inc - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 100 mg in 1 ml - tranexamic acid injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: - in patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity (see warnings). - in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients. - in patients with active intravascular clotting. - in patients with hypersensitivity to tranexamic acid or any of the ingredients.

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

sovereign medical ltd - tranexamic acid - oral tablet - 500mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

rootsallo qwell - calcium carbonate 10.30% alcloxa 0.05% aminocaproic acid 0.05% dibasic calcium phosphate dihydrate 0.30% - anti plaque, anti cavities, healthy gums, prevent gingivitis and perioodontitis,  prevent periodontal disease antiplaque, anticavity, healthy gums toothpaste

Yhdysvallat - englanti - NLM (National Library of Medicine)

red 99 - silicon dioxide 17.0% aminocaproic acid 0.1% aluminum chlorohydroxy allantoinate 0.1% - anti-plaque gum care anti-gingivities 1. tooth removal (anti- plaque) 2. prevention of gingivitis 3. prevention of gum disease

Australia - englanti - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; colloidal anhydrous silica; povidone; hyprolose; titanium dioxide; macrogol 8000; vanillin; basic butylated methacrylate copolymer - hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.

Malta - englanti - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - tranexamic acid - film-coated tablet - tranexamic acid 500 mg - antihemorrhagics

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

manx healthcare ltd - tranexamic acid - oral tablet - 500mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

rivopharm (uk) ltd - tranexamic acid - oral tablet - 500mg